(PLRX) Pliant Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7291391057
PLRX: Fibrosis, Integrin, Inhibitors, Pulmonary, Liver, Cancer, Muscular
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering novel therapies for fibrotic diseases. Its pipeline centers on targeting integrin biology, a critical driver of fibrosis. The companys lead candidate, bexotegrast, is a dual selective inhibitor of avß6 and avß1 integrins, advancing through Phase 2b trials for idiopathic pulmonary fibrosis (IPF) and Phase 2a for primary sclerosing cholangitis (PSC). Additionally, PLN-1474 targets liver fibrosis in nonalcoholic steatohepatitis (NASH), while PLN-101095 and PLN-101325 address solid tumors and muscular dystrophies, respectively. Since its inception in 2015, Pliant has established a robust presence in South San Francisco, California.
Technically, PLRX shows a bearish trend with its price ($1.38) below the 20-day SMA ($4.95), 50-day SMA ($9.37), and 200-day SMA ($12.02). The average volume of 4.9 million and ATR of $0.84 suggest moderate volatility. On the fundamental side, with a market cap of $198.38M, PLRX trades at a P/S of 3050.34, indicating high valuation relative to sales. The negative RoE (-58.32%) reflects ongoing losses, while the P/B of 0.55 points to undervaluation relative to book value.
3-Month Forecast: The stock may face downward pressure due to its current bearish momentum and high valuation multiples. However, positive Phase 2 trial results for bexotegrast could act as a catalyst for upside. Expect volatility with potential price swings between $1.00 and $1.80, influenced by trial outcomes and broader market sentiment.
Additional Sources for PLRX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PLRX Stock Overview
Market Cap in USD | 104m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2020-06-03 |
PLRX Stock Ratings
Growth Rating | -77.9 |
Fundamental | -57.4 |
Dividend Rating | 0.0 |
Rel. Strength | -87.6 |
Analysts | 3.23/5 |
Fair Price Momentum | 1.07 USD |
Fair Price DCF | - |
PLRX Dividends
No Dividends PaidPLRX Growth Ratios
Growth Correlation 3m | -59.5% |
Growth Correlation 12m | -53.6% |
Growth Correlation 5y | -62.9% |
CAGR 5y | -41.87% |
CAGR/Max DD 5y | -0.43 |
Sharpe Ratio 12m | 0.14 |
Alpha | -100.82 |
Beta | 1.165 |
Volatility | 76.00% |
Current Volume | 841.6k |
Average Volume 20d | 747k |
As of May 09, 2025, the stock is trading at USD 1.46 with a total of 841,584 shares traded.
Over the past week, the price has changed by -9.88%, over one month by +19.18%, over three months by -52.44% and over the past year by -89.11%.
No, based on ValueRay Fundamental Analyses, Pliant Therapeutics (NASDAQ:PLRX) is currently (May 2025) a stock to sell. It has a ValueRay Fundamental Rating of -57.39 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PLRX as of May 2025 is 1.07. This means that PLRX is currently overvalued and has a potential downside of -26.71%.
Pliant Therapeutics has received a consensus analysts rating of 3.23. Therefor, it is recommend to hold PLRX.
- Strong Buy: 1
- Buy: 1
- Hold: 11
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, PLRX Pliant Therapeutics will be worth about 1.2 in May 2026. The stock is currently trading at 1.46. This means that the stock has a potential downside of -18.49%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 10.1 | 589% |
Analysts Target Price | 10.1 | 589% |
ValueRay Target Price | 1.2 | -18.5% |